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Abstract
Background: Diabetic retinopathy (DRP) is a common microvascular complication seen in patients with type 1 diabetes
mellitus (T1DM). The effects of T1DM and concomitant (proliferative) DRP on retinal blood flow are currently unclear.
Therefore, we measured retinal vascular blood flow in T1DM patients with and without DRP and non-diabetic controls.
We further assessed the acute effects of panretinal photocoagulation on retinal microvascular bloodflow in eight
patients with diabetes.
Methods: Thirty-three T1DM patients with proliferative DRP, previously treated with panretinal photocoagulation (pDRP),
11 T1DM patients with untreated non-proliferative retinopathy (npDRP) and 32 T1DM patients without DRP (nDRP) were
compared with 44 non-diabetic gender-matched controls. Using scanning laser Doppler flowmetry (HRF, Heidelberg)
blood flow in the retinal microvasculature was measured temporal and nasal of the optic disc and averaged into one
flow value per eye. The right eye was used as a default for further analyses. Eight patients with novel proliferative
retinopathy (4 T1DM and 4 with type 2 diabetes) were measured before and several months after photocoagulation.
Between-group differences in retinal blood flow were assessed using ANOVA corrected for multiple comparisons
(Bonferroni).
Results: Retinal blood flow was higher in the treated pDRP compared with the nDRP group and controls
(all PBonferroni < 0.01). Furthermore, there was a positive linear trend for blood flow with lowest blood flow in
the control group and highest in the pDRP group (P-for-trend < 0.01). In the eight patients with novel proliferative
retinopathy, blood flow did not significantly change before and after panretinal photocoagulation (P > 0.05). Using
regression analysis, no variables were found as predictors of retinal blood flow.
Conclusions: In comparison with controls and nDRP patients, retinal blood flow significantly increased in the pDRP
group, which previously underwent photocoagulation treatment, but not in the npDRP patients. These changes may
be a consequence of a failing vascular autoregulation in advanced diabetic retinopathy.
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Background
Diabetic retinopathy, a highly prevalent complication of
diabetes mellitus, is globally an important cause of
blindness in developed as well as developing nations
[1, 2]. Chronic hyperglycemia is one of the most
important contributing factors [3, 4].
Retinal hemodynamics are thought to be disturbed by
progressive diabetic retinopathy. Hitherto, studies
assessing retinal blood flow in diabetes patients have
shown conflicting results. Several of these studies
showed an increased retinal blood flow in diabetes
patients with no or minimal retinopathy relative to
controls [5, 6], whereas other studies did not note a
difference or found decreased blood flow [7, 8]. These
differing results could be explained by differences in
methodology used, the inclusion of both type 1 and type
2 diabetes patients and sample sizes. The mechanisms of
the changing hemodynamic response of the retina in
both type 1 and type 2 diabetes are largely unknown. A
hypothesis is that chronic hyperglycemia causes loss of
pericytes, which play a role in regulating vascular
tone, and loss of endothelial cells promotes retinal
hemodynamic changes [3]. Alternatively, fluctuations
in blood glucose levels known to acutely alter retinal
blood flow are also thought to contribute to micro-
vascular damage [9].
To better understand the changes in retinal blood flow
in type 1 diabetes we performed a uniform method of
retinal flow measurement in patients without retinop-
athy, with non-proliferative and photocoagulated prolif-
erative retinopathy in comparison with gender-matched
non-diabetic controls. To understand the acute effects of
laser photocoagulation on retinal blood flow we included
8 patients with diabetes in a substudy and performed the
same measurements before and after coagulation.
Methods
Study population
For retinal blood flow measurements, 35 patients
without DRP, 12 with non-proliferative DRP, 35 with
proliferative DRP with T1DM and 45 gender-matched
healthy controls were included in this study. This
study is a sub-study of a study, which focused on
cognitive functioning and brain structure in T1DM,
in relation to the presence or absence of proliferative
DRP [10]. Participants were recruited from outpatient
clinics of the departments of Internal Medicine/Diabetes
Center and Ophthalmology, VU University Medical
Center, Amsterdam, The Netherlands, and from affiliated
hospitals in the Amsterdam area, as well as via advertise-
ments in diabetes specific magazines and a national news-
paper. Controls were recruited through participating
T1DM patients. To determine the effects of panretinal
photocoagulation, we performed a substudy and included
4 type 1 and 4 type 2 diabetes patients newly diagnosed
with proliferative retinopathy. Type 2 diabetes patients
were included as well, because the aim of this substudy
was to investigate changes in blood flow after panretinal
photocoagulation, which is applicable to both type 1 and
type 2 diabetes patients.
Main study: blood flow measurements in type 1 diabetes
patients in different stages of diabetic retinopathy
Inclusion criteria for all participants from the first study
were: age between 18 and 56 years, proficient in Dutch,
right-handedness, and for type 1 diabetes patients a
disease duration of at least ten years. Participants were
excluded in the presence of visual acuity below 0.3 in
either eye; MRI (Magnetic Resonance Imaging)-contra-
indications, such as ICD (Implantable Cardioverter
Defibrillator), pregnancy, non-removable metal implants;
history of coma; current or history of cardio- and
cerebrovascular disease, and alcohol abuse; current drug
use, and use of centrally acting medication including
glucocorticoids; or (treatment for) psychiatric comorbid-
ity. Additionally, the following specific ophthalmic
exclusion criteria were formulated: macular degeneration
or macular edema, cataract, functional monocular vision
(identified by the participants’ treating ophthalmologist)
and media opacities preventing good quality scans (iden-
tified during blood flow measurements). Hypertension
was defined as a systolic blood pressure of >140 mmHg,
or a diastolic blood pressure of >90 mmHg or use of
anti-hypertensive medication. Hypertension, as well as
statin use, were additional exclusion criteria for the non-
diabetes controls.
To determine the grade of DRP fundus photography
(Topcon NW 100, Capelle aan den IJssel, the Netherlands)
was performed (EvD) and retinopathy grading was
performed independently by 2 ophthalmologists (AM and
FV) using the European Diabetes (EURODIAB) classifica-
tion [11]. For each eye, one photograph centered on the
macula and one nasally with the optic disc in the center,
was taken (EvD). Only patients with a EURODIAB score
of 0 (no retinopathy), 1 (minimal non-proliferative retin-
opathy) and 5 (treated with panretinal photocoagulation)
were included in this study.
Substudy: changes in blood flow after panretinal
photocoagulation
For measurement before and after panretinal photo-
coagulation, patients 18 years of age or older and of any
diabetes duration with a EURODIAB score of 4 (prolifer-
ative retinopathy) were included. For this study, both
type 1 diabetes mellitus (T1DM) patients and type 2 dia-
betes mellitus (T2DM) patients were included. Exclusion
criteria for this group were the same as the ophthalmic
exclusion criteria mentioned above. Instead of fundus
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photography, these participants were graded by indirect
fundoscopy (TN and AM) or fluorescence angiography
(AM), confirming proliferative diabetic retinopathy.
The tenets from the declaration of Helsinki were
followed and written informed consent was obtained
from all participants. Ethics approval was obtained from
the institutional Ethics Review Board.
Study design
For the main study, during an afternoon visit, blood
samples were drawn for routine assessment, including
HbA1c and lipid levels and 24-h urine sampling was
performed to determine albumin-to-creatinine ratio.
During this visit, retinal blood flow was measured
and capillary current blood glucose level was deter-
mined using finger prick prior to and after blood flow
measurements.
Current blood glucose levels were actively kept
between 4 and 15 mmol/l. If blood glucose levels were
below 4 and above 15 mmol/L, these values were corrected
according to a standardized protocol until they reached the
required range [10]. Eight patients had a blood glucose
level below 4 mmol/l and eight above 15 mmol/l. Thirty
minutes after correction of blood glucose levels all partici-
pants had levels within the required range and blood flow
testing was started.
Retinal blood flow
Scanning laser Doppler flowmetry is a non-invasive
method to measure retinal blood flow [12, 13]. The
principle of scanning laser Doppler flowmetry has been
described in detail elsewhere [12]. Using the Heidelberg
Retinal Flowmeter (HRF) (Heidelberg, Germany), retinal
blood flow images were obtained. Flow measurements
were made without pupillary dilatation. A scanning
window of 10° was used. For measurement of the right
eye, subjects were instructed to look into a fixation point
with the left eye. The lens was held at a minimum
distance of two cm to the cornea of the eye [14].
Subjects were seated at least ten minutes before starting
image acquisition. Retinal blood flow was assessed
temporal and nasal to the optic disc (Fig. 1). Three
consecutive images were obtained from each area and
flow values, obtained with specialized software, were
averaged. Larger retinal vessels were used as landmarks to
ensure that identical sampling areas were scanned during
consecutive measurements. Only subjects with two or
more successful measurements for each area were in-
cluded (mean: 2.65 measurements). Measurements for the
substudy before panretinal coagulation were taken on the
same day of the scheduled first visit for photocoagulation
treatment.
Image analysis
Offline, the Automated Full Field Perfusion Image
Analyser (AFFPIA) version 3.3, which has been validated
as reliable analyzing software by Michelson et al. [15],
was used to analyze the retinal blood flow images. Using
Fourier Transformation, two-dimensional flow maps
were obtained. Large vessels and photocoagulation scars
were manually excluded, leaving only capillaries to be
analyzed. Images were excluded when containing less
than 10 % pixels. Flow values of the same scanning area
of each subject were then averaged. After analysis, the
blood flow value of the measured location was given in
arbitrary units (AU). Within each eye the average of the
flow values nasally and temporally to the optic disc was
taken as single final microvascular flow measurement
for each subject.
Statistical analysis
Statistical analysis was performed using SPSS 15.0
(SPSS, Chicago, IL).
Data were calculated as mean (±SD) for normally
distributed or median (with IQR) for non-normally
distributed variables. Cohen’s kappa coefficient was used
Fig. 1 Retinal blood flow images. Image a is a fundus photograph
of the retina (right eye). The rectangular areas are the temporal (T)
and nasal (N) measurement areas. Image b and c are an example
of an image taken with the Heidelberg Retinal Flowmeter of the
temporal (B) and nasal areas (C) respectively
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to calculate intra-observer reliability. Group differences
for demographical variables were analyzed using an one-
way ANOVA with Bonferroni correction for continuous
variables and chi-square for categorical variables. Be-
cause of non-normal distribution, retinal blood flow
values were log-transformed to allow parametric testing.
Retinal blood flow values were normally distributed after
log-transformation. Student’s t-test was used to calculate
differences between the left and right eye and between
the two measurement areas temporally and nasally to
the optic disc, before averaging both values into one
value. Linear regression was used to determine con-
founders. Differences in retinal blood flow were analyzed
using ANOVA, with Bonferroni correction for multiple
comparisons, and further corrections for confounders.
The level of significance was set as P = 0.05.
Substudy
Student’s t-test was used to calculate differences in
retinal blood flow before and after panretinal photo-
coagulation. The level of significance was set as P = 0.05.
Results
Subjects
Of all subjects included, two patients with proliferative
DRP, 1 with non-proliferative DRP, three without DRP
and 1 control subject were excluded from further
analysis due to insufficient quality of the measurements.
Since there were no significant differences between the
right and left eye for all groups separately (P > 0.05), the
right eye was used as default for further analyses, as
most data were available for the right eye. If data of the
right eye were unavailable, the left eye was used instead.
For the final analyses 33 patients with proliferative DRP,
11 with non-proliferative DRP, 32 without DRP and 44
controls (110 right eyes and 10 left eyes) were included.
Table 1 displays subjects’ characteristics.
Groups differed with regard to age, diabetes duration,
systolic blood pressure, HbA1c and hypertension (all
P < 0.01). Post-hoc testing showed that the group with
proliferative DRP was significantly older than the
group without DRP and controls, had higher systolic
blood pressure relative to the patients without DRP
and control subjects and had longer disease duration
than the group without DRP (all P < 0.05). There was
no statistically significant difference in mean current
blood glucose among the T1DM groups (P > 0.05).
Retinal blood flow
To assess intra-observer reliability, ten images from
different subjects were randomly selected to be analyzed
with the AFFPIA software by the same observer (HN)
six months after initial analysis. The intra-class correl-
ation coefficient (κ) was 0.99 for both the temporal and
nasal measurement areas, which is in line with previous
literature [16].
Figure 2 shows retinal blood flow values (in AU) of all
groups. Median flow value (in AU) with corresponding
interquartile ranges was 200.9 (±55.0) for controls, 216.8
(±67.2) for nDRP, 229.5 (±87.8) for npDRP and 253.1
(±89.9) for pDRP. Blood flow in the pDRP group was
significantly increased compared to the nDRP group (mean
absolute difference: 47.4; mean log difference: 0.198; 95 %
Confidence Interval (CI): 0.036–0.331; P = 0.001) and
Table 1 Demographic and laboratory variables in T1DM patients and controls
Controls T1DM no DRP T1DM non-proliferative DRP T1DM proliferative DRP (treated) P
N 44 32 11 33
Age (years) 38 (11.3) 38 (8.7) 36 (5.4) 45 (7.7) <0.001
Gender (m/f) 18/26 10/22 4/7 15/18 0.687
Systolic blood pressure (mmHg) 124 (12) 131 (17) 121 (11) 136 (19) <0.01
Diastolic blood pressure (mmHg) 78 (8) 77 (9) 76 (5) 77 (9) 0.941
Diabetes duration (years) – 22 (8.5) 22 (7.6) 34 (6.6) <0.001
Hypertension (%)a – 8 (25 %) 2 (18 %) 21 (66 %) <0.001
Current blood glucose (mmol/l)b – 8.2 (3.2) 8.4 (3.2) 9.7 (5.0) 0. 321
HbA1c (%) 5.3 (0.2) 7.9 (0.9) 7.8 (1.1) 8.1 (1.4) <0.001
Albumin-to-creatinine ratioc – 0.8 (1.0) 0.5 (0.6) 3.3 (6.7) 0.059
Neuropathy (%)d – 1 (3) 0 15 (47) <0.01
Nephropathy (%)e – 0 0 6 (19) <0.01
Data are mean ± standard deviation or absolute number with percentages. P-values for overall one-way ANOVA are shown
aHypertension was defined as a systolic blood pressure of 140 mmHg or above, a diastolic blood pressure of 90 mmHg or above or use of anti-hypertensive medication
bCurrent blood glucose level was measured using a finger prick
cAlbumin-to-creatinine ratio was determined in 24-h urine sampling
dNeuropathy was self-reported or obtained from medical records
eNephropathy was based on a 24-h urine sample and defined as an ACR of 2.5 or above for men and 3.5 for women
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compared with controls (mean absolute difference
59.5; mean log difference: 0.255; 95 % CI: 0.131–
0.378; P = 0.000). Between groups, there was a signifi-
cant positive linear trend for blood flow (P < 0.01;
Fig. 2) with lowest flow in the control group and in-
creasing with diabetic retinopathy severity. This trend
remained significant (P < 0.01) after excluding the
DRP group from the analysis. Using linear regression,
blood glucose levels, HbA1c, diabetes duration, age,
gender, hypertension, albumin/creatinine ratio and
various other variables were not found to be predic-
tors of retinal blood flow for all groups (P > 0.05).
As hypertension can significantly influence blood flow
measurements we have additionally repeated the analysis
in patients and controls without hypertension only.
Firstly, median flow for T1DM patients with hyperten-
sion did not significantly differ from the flow in patients
without hypertension (236.7 and 249.7 AU respectively
[P = 0.170]). After excluding participants with hyperten-
sion, an analysis was performed with 12 patients in de
pDRP group, 9 patients in the npDRP group and 24
patients in the nDRP group. The median flow for the
pDRP group was 246.4 AU, for the npDRP group
228.15 AU and for the nDRP group this was 224.4 AU.
As none of the controls were excluded, the median flow
in this group did not change (200.9 AU). Despite the
apparent loss of sample size and thus statistical power,
in the presence of an increased standard deviation this
exploratory analysis showed results similar to the
whole group analysis. There was an overall effect of
group (P = 0.001) and a significant linear trend over
the groups (P < 0.01, Fig. 3). After Bonferroni correction
blood flow was higher in the pDRP group compared to
controls (P = 0.003). There were no significant differences
in blood flow between the pDRP group and the other
groups.
Substudy: retinal blood flow before and after panretinal
photocoagulation
Eight eyes of 8 participants (4 T1DM patients and 4
T2DM patients) were included for blood flow measure-
ments before and after panretinal photocoagulation
(PRP). Table 2 displays subjects’ characteristics.
Mean age was 48.9 years (range 24–84 years), mean
diabetes duration was 19.2 years (3 months to 34 years).
Fig. 2 Blood flow values. Box-plot of absolute retinal blood flow values
(in Arbitrary Units) showing medians, quartiles, maximum and minimum
values. Significant P-values for the linear trend and post-hoc tests
pairwise comparisons after MANCOVA are shown. Controls (N= 44), no
retinopathy (N = 32), non-proliferative retinopathy (N= 11), proliferative
retinopathy (N = 33)
Fig. 3 Blood flow values after excluding hypertensive T1DM participants.
Box-plot of absolute retinal blood flow values (in Arbitrary Units) showing
medians, quartiles, maximum and minimum values. Significant P-values
for the linear trend and post-hoc tests pairwise comparisons
after MANCOVA are shown. Controls (N = 44), no retinopathy (N = 12),
non-proliferative retinopathy (N = 9), proliferative retinopathy (N = 24)
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Blood glucose in this group ranged from 5.60 mmol/l to
15.8 mmol/l, with a mean of 9.7 mmol/l. Systolic blood
pressure ranged from 122 mmHg to 170 mmHg, mean
systolic blood pressure was 140 mmHg. Time between
completion of panretinal photocoagulation and blood
flow measurement ranged from 2 to 12 months. Figure 4
shows retinal blood flow before and after panretinal
photocoagulation. Blood flow did not significantly
change after panretinal photocoagulation, compared
to before panretinal photocoagulation (P > 0.05, paired
T-test). When adding follow-up time as a covariate,
change over time remained statistically non-significant
(P = 0.404). When analyzing the T1DM and T2DM
patients separately, we saw similar results in both
groups. In the T1DM group, blood flow before pan-
retinal photocoagulation was 211.9 AU, whereas after
photocoagulation this increased to 220.7 AU (P = 0.28,
paired T-test). In the T2DM group blood flow before
panretinal photocoagulation was 222.4 AU and after
photocoagulation increased to 230.6 AU (P = 0.303,
paired T-test).
Discussion
Our results show increased retinal blood flow in T1DM
patients with documented signs of retinopathy. This
increased blood flow was most pronounced in patients
with treated proliferative retinopathy, although a signifi-
cant linear trend toward increased blood flow with
increasing severity of retinopathy was found in type 1
diabetes patients. This may indicate that retinal blood
Table 2 Demographic and laboratory variables in T1DM and T2DM patients before and after panretinal laser photocoagulation








1 63 1 34 years 145/78 6.5 20 2
143/70 15.7 18
2 47 1 16 years 127/92 7.2 14 7
130/96 8.9 15
3 45 1 30 years 144/85 13.5 13 10
140/82 12.6 13
4 24 1 16 years 145/83 5.6 14 12
122/80 5.6 16
5 46 2 20 years 138/78 5.9 12 3
138/78 15.8 14
6 43 2 6 years 170/95 8.5 18 3
164/84 6.5 16
7 84 2 21 years 122/81 6.6 13 3
130/78 7.5 15
8 42 2 3 months (from diagnosis) 176/94 6.7 20 7
150/90 5.6 18
Data shown for blood pressure, blood glucose and intra-ocular pressure (IOP) represents the measurents before (upper) and after (lower) panretinal photocoagulation
Fig. 4 Blood flow before and after panretinal photocoagulation.
Individual absolute blood flow values (AU) of 7 right eyes and 1 left
eye of patients with type 1 and type 2 DM and proliferative diabetic
retinopathy before and after panretinal photocoagulation. The red
lines represent the type 1 DM patients and the blue lines represent
the type 2 DM patients respectively. The asterisk indicates the mean
blood flow values before and after panretinal photocoagulation
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flow gradually increases in type 1 diabetes patients who
develop retinopathy. The increased blood flow was
related to the presence of retinopathy itself, but not
associated with current blood glucose level, HbA1c, dia-
betes duration, age, gender, or hypertension. A disturbed
retinal blood flow in progressed retinopathy might be
expected, since it indicates a damaged microcirculation.
Whether retinal blood flow increases in early diabetic
retinopathy is unclear, since previous studies focusing on
retinal blood flow changes in early stages of retinopathy
have reported conflicting results [6–8, 17–20].
Interestingly, in the proliferative DRP group we found
a statistically significant higher capillary blood flow as
compared to the non-DRP group and controls. This
group had previously been treated with panretinal
photocoagulation. Studies investigating VEGF levels and
blood flow in major retinal vessels suggest a decrease in
blood flow after panretinal photocoagulation compared
to pre-treatment [21–24]. Blood flow, measured in the
larger retinal arteries, was found to decrease after retinal
photocoagulation in these studies. To investigate whether
panretinal photocoagulation changes retinal blood flow,
we measured blood flow in a group of type 1 and type 2
diabetes patients with proliferative diabetic retinopathy
before and after panretinal photocoagulation. In partial
support of our findings, Cuypers et al. [17], using the same
method, reported capillary blood flow to be increased in
proliferative retinopathy as measured in the papillo-
macular area and unchanged in other parts of the retina
[17]. In pDRP two important hemodynamic changes are
present. Firstly, this group has a more compromised
vascular system with a more decreased autoregulatory
function [25]. Secondly, panretinal photocoagulation
destroys a significant part of the retinal microcirculation,
but larger vessels are left intact. Blood from larger vessels
then enters a damaged microcirculation with a diminished
number of capillaries. This changed distribution of blood
and decreased autoregulation function of the retinal
vessels might lead to a higher flow in these capillaries.
Capillary drop-out and peripheral areas of non-perfusion
are present in proliferative diabetic retinopathy [26]. As
we did not find extremely low blood flow values in the
pDRP group, it can be assumed that capillary drop-out
was modest in the measured areas. The peripheral retina
could not be measured using our technique and therefore,
and because our measurements were limited to the peri-
papillary area, we are not able to extrapolate our findings
to the entire retina. Hemodynamic changes are thought to
parallel diabetic retinopathy progression and possibly even
precede visible fundus changes. Studies have found
differences in retinal and choroidal blood flow in relation
to retinopathy severity [7, 8]. One study found changes in
retinal blood flow in diabetic patients without retinopathy
[6]. We found a significant positive linear trend for blood
flow between the groups. This linear trend indicates
that with progressing severity of diabetic retinopathy,
retinal blood flow is associated with an increase as
well. It may suggest that retinal blood flow is already
altered in T1DM without clinically manifest signs of
retinopathy. The linear trend persisted after excluding
hypertensive patients from the analysis. Furthermore,
it is known that elevated blood glucose levels increase
retinal blood flow [9]. In this study, we did not find
an association between blood glucose levels during
retinal blood flow measurement and retinal blood
flow. Therefore this could not have confounded our
results in de pDRP group.
Both hypertension and vasodilatory medication, such
as some antihypertensive medication, could have an
effect on blood flow and thus confound our results.
Therefore, we repeated our main analysis excluding all
patients with hypertension (which also included those
using antihypertensive medication). Despite the loss of
sample size and statistical power, this analysis showed
similar results. Furthermore, blood flow was not signifi-
cantly different between the groups with and without
hypertension and hypertension was not related to blood
flow in the regression analysis performed in the whole
group. Taken together this suggests that in this group
of patients hypertension did not confound our blood
flow findings.
Our findings in control subjects differ from the
findings of Michelson et al. as they have measured
higher blood flow (in Arbitrary Units) [15]. We have
measured blood flow with a 790 nm HRF setting
whereas Michelson et al. employed a 690 nm HRF
setting, which could possibly lead to differences in
measurement values. Although overall higher blood
flow was found in their study, the relative differences
were similar. In their study, blood flow nasally to the
optic disc was more increased than temporally to the
optic disc, corresponding to our findings.
Although this is a study with well phenotyped T1DM
patients with different stages of retinopathy, some limi-
tations have to be mentioned. First, the pDRP group has
undergone panretinal laser photocoagulation. Therefore,
to determine the effect of panretinal laser photocoagula-
tion, we included several type 1 and type 2 diabetes
patients in a substudy. We did not find any significant
change in blood flow before and after panretinal
photocoagulation, although the substudy was limited
by a small sample size and variable time to follow up
(2–12 months). This variable follow-up time was due
to a number of participants not showing up for the
routine check-up after laser photocoagulation and
adjusting for this did not change the results. Second,
the intraocular pressure (IOP) was not determined in
T1DM patients. Substantially elevated IOP would
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result in lowering of retinal blood flow [27]. Intraocular
pressure has been shown to be only marginally elevated in
patients with T1DM [28]. Nevertheless, in our study we
demonstrated increased blood flow values in the diabetic
patients, so the effect of IOP would counteract our results.
Control participants were excluded when having hyper-
tension or dyslipidemia. This was chosen as participants
included were of a young age (mean age 38 years) with an
upper limit of 56 years, and in such young people hyper-
tension and dyslipidemia are often part of the metabolic
syndrome or another disorder, which excludes participants
from being healthy. Lastly, patients with pDRP are
older compared with the other groups. This is a natural
phenomenon as it takes 15–25 or more years to reach the
proliferative stage of DRP, if it develops at all. Given this
age difference, we decided to carefully match in terms of
age the control group to the groups without pDRP. To
limit the effect of age on the results, it was treated as a
confounding factor in all analyses.
Finally it is worth mentioning that measurements
with scanning laser Doppler flowmetry must be inter-
preted with caution. There is ongoing debate on what
exactly is measured with this technique. Using experi-
mental models, studies have shown that scanning
laser Doppler flowmetry measures blood flow in the
larger and smaller elements of the retinal microvascu-
lature [29, 30]. It would have been interesting to also
measure the large vessels as well as the choroidal
circulation to capture a more complete picture of
retinal blood flow. Unfortunately, due to technical
limitations of the Heidelberg Retinal Flowmeter and
using the AFFPIA software, it is not capable of cap-
turing flow in these locations [31, 32].
Conclusion
In conclusion, an increased retinal blood flow was ob-
served in T1DM patients with treated and untreated
proliferative retinopathy and blood flow seems to in-
crease in increasing severity of retinopathy. We found
no difference in retinal blood flow before and after pan-
retinal laser photocoagulation for proliferative diabetic
retinopathy. How these hemodynamic changes develop
over time and what the underlying mechanisms are,
remains unclear. Future prospective research is needed
to elucidate the changes in blood flow over time which
accompany a failing retinal vasculature in T1DM.
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